{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:20:08Z","timestamp":1792174808400,"version":"4.4.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008810","name":"NSW Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008810","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020670","name":"Cancer Council Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022513","name":"Tasmanian Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001139","name":"ACT Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health, Disability and Ageing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001231","name":"VicHealth","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001231","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jval.2026.06.018","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:24:30Z","timestamp":1784042670000},"page":"1825-1835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Introducing Risk Stratification Reduces Patient Burden and Improves Cost-Effectiveness of Hepatocellular Carcinoma Surveillance for People With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Modeling Study"],"prefix":"10.1016","volume":"29","author":[{"given":"Joachim","family":"Worthington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon A.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Feletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2026.06.018_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/1753-6405.12889","article-title":"Increasing incidence and mortality related to liver cancer in Australia: time to turn the tide","volume":"43","author":"Cocker","year":"2019","journal-title":"Aust N Z J Public Health"},{"issue":"1","key":"10.1016\/j.jval.2026.06.018_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/s13104-020-05395-6","article-title":"Changes in cancer incidence and mortality in Australia over the period 1996-2015","volume":"13","author":"Luo","year":"2020","journal-title":"BMC Res Notes"},{"issue":"6","key":"10.1016\/j.jval.2026.06.018_bib3","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1016\/S2468-2667(22)00090-1","article-title":"Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study","volume":"7","author":"Luo","year":"2022","journal-title":"Lancet Public Health"},{"issue":"6","key":"10.1016\/j.jval.2026.06.018_bib4","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jval.2026.06.018_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Prim"},{"issue":"3","key":"10.1016\/j.jval.2026.06.018_bib6","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/liv.13966","article-title":"Hepatocellular carcinoma in Australia 1982-2014: increasing incidence and improving survival","volume":"39","author":"Wallace","year":"2019","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.jval.2026.06.018_bib7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.5694\/mja18.00373","article-title":"Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study","volume":"209","author":"Hong","year":"2018","journal-title":"Med J Aust"},{"issue":"10","key":"10.1016\/j.jval.2026.06.018_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5694\/mja2.50885","article-title":"Australian recommendations for the management of hepatocellular carcinoma: a consensus statement","volume":"214","author":"Lubel","year":"2020","journal-title":"Med J Aust"},{"issue":"8","key":"10.1016\/j.jval.2026.06.018_bib9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.5694\/mja2.70061","article-title":"Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations","volume":"223","author":"George","year":"2025","journal-title":"Med J Aust"},{"issue":"6","key":"10.1016\/j.jval.2026.06.018_bib10","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jval.2026.06.018_bib11","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.jval.2026.06.018_bib12","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/imj.15689","article-title":"Hepatocellular carcinoma (HCC) is changing its face: analysis of the temporal trends in aetiology and clinical patterns of HCC in South Australia","volume":"53","author":"Chandran","year":"2023","journal-title":"Int Med J"},{"issue":"9","key":"10.1016\/j.jval.2026.06.018_bib13","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/jgh.15009","article-title":"Nonalcoholic fatty liver disease burden: Australia, 2019-2030","volume":"35","author":"Adams","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jval.2026.06.018_bib14","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/imj.16252","article-title":"Temporal change in aetiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients in New South Wales, Australia","volume":"54","author":"Yeoh","year":"2024","journal-title":"Intern Med J"},{"issue":"2","key":"10.1016\/j.jval.2026.06.018_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3350\/cmh.2022.0316","article-title":"Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990-2019: a DALY-based analysis of the Global Burden of Disease 2019 study","volume":"29","author":"Choi","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"10.1016\/j.jval.2026.06.018_bib16","article-title":"Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021","volume":"7","author":"Feng","year":"2025","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.jval.2026.06.018_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jval.2026.06.018_bib18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"23","author":"Tan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2026.06.018_bib19","series-title":"Clinical Characteristics and Surveillance Patterns in Hepatocellular Carcinoma Patients in Australia","author":"He","year":"2024"},{"issue":"5","key":"10.1016\/j.jval.2026.06.018_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.5694\/mja2.70008","article-title":"Assessment of metabolic dysfunction-associated fatty liver disease in primary care: a consensus statement summary","volume":"223","author":"Adams","year":"2025","journal-title":"Med J Aust"},{"key":"10.1016\/j.jval.2026.06.018_bib21","series-title":"Novel biomarkers of hepatocellular carcinoma","author":"Cheng","year":"2018"},{"issue":"3","key":"10.1016\/j.jval.2026.06.018_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1055-9965.EPI-18-0281","article-title":"GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score","volume":"28","author":"Yang","year":"2019","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"2","key":"10.1016\/j.jval.2026.06.018_bib23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ijc.10122","article-title":"Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan","volume":"98","author":"Chen","year":"2002","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.jval.2026.06.018_bib24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"issue":"6","key":"10.1016\/j.jval.2026.06.018_bib25","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review","volume":"158","author":"Loomba","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jval.2026.06.018_bib26","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2026.06.018_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.puhe.2025.03.030","article-title":"The potential for primary and secondary prevention of liver cancer death in Australians with alcohol-related liver disease or metabolic-associated steatotic liver disease: a modelling study","volume":"243","author":"Worthington","year":"2025","journal-title":"Public Health"},{"issue":"4","key":"10.1016\/j.jval.2026.06.018_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16119","article-title":"Pharmaco-economic assessment of screening strategies for high-risk MASLD in primary care","volume":"45","author":"Younossi","year":"2025","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.jval.2026.06.018_bib29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.5694\/mja2.52124","article-title":"Hepatocellular carcinoma surveillance in Australia: current and future perspectives","volume":"219","author":"Hui","year":"2023","journal-title":"Med J Aust"},{"issue":"6","key":"10.1016\/j.jval.2026.06.018_bib30","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jval.2026.06.018_bib31","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(24)00437-0","article-title":"Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis","volume":"10","author":"Liguori","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jval.2026.06.018_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jhep.2020.04.034","article-title":"STELLAR. STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus","volume":"73","author":"Rinella","year":"2020","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jval.2026.06.018_bib33","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/hep.24581","article-title":"Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?","volume":"54","author":"Poustchi","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jval.2026.06.018_bib34","article-title":"A health economic evaluation of routine hepatocellular carcinoma surveillance for people with compensated cirrhosis to support Australian clinical guidelines","volume":"10","author":"Worthington","year":"2025","journal-title":"MDM Policy Pract"},{"issue":"5","key":"10.1016\/j.jval.2026.06.018_bib36","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/0272989X251333398","article-title":"Evaluating semi-Markov processes and other epidemiological time-to-event models by computing disease sojourn density as partial differential equations","volume":"45","author":"Worthington","year":"2025","journal-title":"Med Decis Making"},{"issue":"6","key":"10.1016\/j.jval.2026.06.018_bib40","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jval.2026.06.018_bib41","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eprac.2022.03.016","article-title":"Metabolic associated fatty liver disease (MAFLD) increases the risk of systemic complications and mortality. A meta-analysis and systematic review of 12,620,736 individuals","volume":"28","author":"Quek","year":"2022","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.jval.2026.06.018_bib42","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jhep.2021.08.016","article-title":"Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population","volume":"75","author":"Nielsen","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jval.2026.06.018_bib43","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"M\u00f3zes","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jval.2026.06.018_bib44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12876-022-02290-1","article-title":"Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups","volume":"22","author":"Sugiyama","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.jval.2026.06.018_bib45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10620-012-2306-1","article-title":"Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation","volume":"58","author":"Kumar","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"7143","key":"10.1016\/j.jval.2026.06.018_bib46","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1136\/bmj.316.7143.1529","article-title":"Perspectives in economic evaluation","volume":"316","author":"Byford","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2026.06.018_bib47","author":"Parkinson"},{"issue":"2","key":"10.1016\/j.jval.2026.06.018_bib48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40273-017-0585-2","article-title":"Estimating the reference incremental cost-effectiveness ratio for the Australian health system","volume":"36","author":"Edney","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.jval.2026.06.018_bib49","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jval.2018.01.017","article-title":"Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC\u2014does the presence of an explicit threshold affect the ICER proposed?","volume":"21","author":"Wang","year":"2018","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2026.06.018_bib50","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jval.2026.06.018_bib51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/sono.12239","article-title":"Providing a sustainable sonographer workforce in Australia: clinical training solutions","volume":"7","author":"McGregor","year":"2020","journal-title":"Sonography"},{"issue":"2","key":"10.1016\/j.jval.2026.06.018_bib52","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.32655","article-title":"Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis","volume":"77","author":"Chang","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jval.2026.06.018_bib53","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/HEP.0000000000000364","article-title":"Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: a development and validation study","volume":"78","author":"Lee","year":"2023","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.jval.2026.06.018_bib54","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.jval.2021.04.1286","article-title":"Cost-Effectiveness of a serum biomarker test for risk-stratified liver ultrasound screening for Hepatocellular Carcinoma","volume":"24","author":"Carter","year":"2021","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2026.06.018_bib55","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.cgh.2025.10.029","article-title":"Novel machine-learning models outperform non-invasive tests in MASH with fibrosis","volume":"24","author":"Stefanakis","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.jval.2026.06.018_bib56","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/apt.17472","article-title":"The combination of the enhanced liver fibrosis and FIB-4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease","volume":"57","author":"Younossi","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jval.2026.06.018_bib57","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jval.2026.06.018_bib58","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.jval.2026.06.018_bib59","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jval.2026.06.018_bib60","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","article-title":"Global multi-stakeholder endorsement of the MAFLD definition","volume":"7","author":"M\u00e9ndez-S\u00e1nchez","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jval.2026.06.018_bib61","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.945198","article-title":"Why MASLD lags behind MAFLD: a critical analysis of diagnostic criteria evolution in metabolic dysfunction-associated liver diseases","volume":"30","author":"Alboraie","year":"2024","journal-title":"Med Sci Monit"},{"issue":"21","key":"10.1016\/j.jval.2026.06.018_bib62","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jval.2026.06.018_bib63","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.3390\/jcm12196216","article-title":"Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: the patient and physician perspective","volume":"12","author":"Eskridge","year":"2023","journal-title":"JCM"},{"key":"10.1016\/j.jval.2026.06.018_bib64","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/JMDH.S359084","article-title":"Potential for use of portable ultrasound devices in rural and remote settings in Australia and other developed countries: a systematic review","volume":"15","author":"Shaddock","year":"2022","journal-title":"JMDH"},{"issue":"3","key":"10.1016\/j.jval.2026.06.018_bib65","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/sono.12198","article-title":"A discussion paper on key issues impacting the sonographer workforce in Australia","volume":"6","author":"Bowman","year":"2019","journal-title":"Sonography"},{"issue":"2","key":"10.1016\/j.jval.2026.06.018_bib67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5694\/mja2.52691","article-title":"Opportunities to improve surveillance of hepatocellular carcinoma in Australia","volume":"223","author":"Howell","year":"2025","journal-title":"Med J Aust"},{"issue":"7","key":"10.1016\/j.jval.2026.06.018_bib68","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5694\/mja2.50521","article-title":"Hepatocellular carcinoma surveillance in Australia: time to improve the diagnosis of cirrhosis and use liver ultrasound","volume":"212","author":"Jeffrey","year":"2020","journal-title":"Med J Aust"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:46:12Z","timestamp":1791258372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526025386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1098301526025386"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.06.018","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Introducing Risk Stratification Reduces Patient Burden and Improves Cost-Effectiveness of Hepatocellular Carcinoma Surveillance for People With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Modeling Study","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}